Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits

Chinese Medical Journal

Volumn 127, Issue 16, 2014, Pages 2953-2959

  Wang, Xiao Qiao ^a   Lin, Yong Qin ^b,c   Luo, Nian Sang ^b,c   Chen, Zhong Qing ^a   Gu, Miao Ning ^a   Wang, Jing Feng ^b,c   Chen, Yang Xin ^b,c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology   (China)

Author keywords

5 lipoxygenase pathway; Adipose tissue; Atorvastatin; Endothelial function; Inflammation

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADIPOSE TISSUE; ANIMAL; DRUG EFFECTS; HYPERLIPIDEMIAS; IMMUNOLOGY; INFLAMMATION; LIPID METABOLISM; MALE; METABOLISM; RABBIT;

ADIPOSE TISSUE; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; HEPTANOIC ACIDS; HYPERLIPIDEMIAS; INFLAMMATION; LIPID METABOLISM; MALE; PYRROLES; RABBITS;

EID: 84906483842     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20133011     Document Type: Article

References (33)

1. Damås JK, Puccetti L, Aukrust P. Early anti-thrombotic and anti-inflammatory actions of statins and fibrates-time for adjuvant therapy in acute coronary syndromes? Thromb Haemost 2005; 94: 1-3.
2. Sparrow CP, Burton CA, Hernandez M. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115-121.
3. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007; 28: 664-672.
4. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007; 49: 290-297.
5. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1405-1410.
6. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
7. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs: usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-2445.
8. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 2005; 96: 61F-68F.
9. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-1278.
10. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54: 2157-2163.
11. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678.
12. Matsuzawa Y, Sugiyama S, Sumida H, Sugamura K, Nozaki T, Ohba K, et al. Peripheral endothelial function and cardiovascular events in high-risk patients. J Am Heart Assoc 2013; 2: e000426.
13. Gupta AK, Ravussin E, Johannsen DL, Stull AJ, Cefalu WT, Johnson WD. Endothelial dysfunction: an early cardiovascular risk marker in asymptomatic obese individuals with prediabetes. Br J Med Med Res 2012; 2: 413-423.
14. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007; 115: 2390-2397.
15. Sawada T, Emoto T, Motoji Y, Hashimoto M, Kageyama H, Terashita D, et al. Possible association between non-invasive parameter of flow-mediated dilatation in brachial artery and whole coronary plaque vulnerability in patients with coronary artery disease. Int J Cardiol 2013; 166: 613-620.
16. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115-121.
17. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007; 28: 664-672.
18. Bäck M, Sultan A, Ovchinnikova O, Hansson GK. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 2007; 100: 946-949.
19. Horrillo R, González-Périz A, Martínez-Clemente M, López-Parra M, Ferré N, Titos E, et al. 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol 2010; 184: 3978-3987.
20. González-Périz A, Clària J. Resolution of adipose tissue inflammation. Sci World J 2010; 10: 832-856.
21. Chen YX, Wang XQ, Fu Y, Yao YJ, Kong MY, Nie RQ, et al. Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin. Int J Cardiol 2011; 146: 140-144.
22. Kobayasi R, Akamine EH, Davel AP, Rodrigues MA, Carvalho CR, Rossoni LV. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice. J Hypertens 2010; 28: 2111-2119.
23. Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008; 28: 1654-1659.
24. Zhang H, Potter BJ, Cao JM, Zhang C. Interferon-gamma induced adipose tissue inflammation is linked to endothelial dysfunction in type 2 diabetic mice. Basic Res Cardiol 2011; 106: 1135-1145.
25. Filip M, Maciag J, Nosalski R, Korbut R, Guzik T. Endothelial dysfunction related to oxidative stress and inflammation in perivascular adipose tissue. Postepy Biochem 2012; 58: 186-194.
26. Chen Y, Wang X, Mai J, Zhao X, Liang Y, Gu M, et al. C-reactive protein promotes vascular endothelial dysfunction partly via activating adipose tissue inflammation in hyperlipidemic rabbits. Int J Cardiol 2013; 168: 2397-2403.
27. Yang LX, Heng XH, Guo RW, Si YK, Qi F, Zhou XB. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice. J Cardiovasc Pharmacol 2013; 62: 205-211.
28. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, et al. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res 2006; 71: 363-373.
29. Gao YJ, Lu C, Su LY, Sharma AM, Lee RM. Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol 2007; 151: 323-331.
30. Ketonen J, Shi J, Martonen E, Mervaala E. Periadventitial adipose tissue promotes endothelial dysfunction via oxidative stress in diet-induced obese C57Bl/6 mice. Circ J 2010; 74: 1479-1487.
31. Verhagen SN, Visseren FL. Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis 2011; 214: 3-10.
32. Verhagen SN, Vink A, van der Graaf Y, Visseren FL. Coronary perivascular adipose tissue characteristics are related to atherosclerotic plaque size and composition. A post-mortem study. Atherosclerosis 2012; 225: 99-104.
33. Öhman MK, Luo W, Wang H, Guo C, Abdallah W, Russo HM, et al. Perivascular visceral adipose tissue induces atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2011; 219: 33-39.